Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

Experimental Neurology

Volumn 187, Issue 1, 2004, Pages 137-149

  Schilling, Gabriele ^a   Savonenko, Alena V ^a   Coonfield, Michael L ^a   Morton, Johanna L ^a   Vorovich, Esther ^a   Gale, Alexa ^a   Neslon, Christopher ^a   Chan, Ning ^a   Eaton, Michelle ^a   Fromholt, David ^a   Ross, Christopher A ^a   Borchelt, David R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coenzyme Q10; Drug trial; Environmental enrichment; HD N171 82Q transgenic mice; Huntington's disease; Remacemide hydrochloride

Indexed keywords

ANTIOXIDANT; CELECOXIB; CHLORPROMAZINE; COPPER; GLUTAMATE RECEPTOR ANTAGONIST; HUNTINGTIN; NITROGEN; PROSTAGLANDIN SYNTHASE INHIBITOR; REMACEMIDE; SUPEROXIDE DISMUTASE; UBIDECARENONE; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; ENVIRONMENTAL FACTOR; FEMALE; HIGH RISK POPULATION; HUNTINGTON CHOREA; LIFE EXPECTANCY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ACETAMIDES; ANIMALS; CHLORPROMAZINE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE ANTAGONISTS; ENVIRONMENT, CONTROLLED; FEMALE; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR SKILLS; NEUROPROTECTIVE AGENTS; PHENOTYPE; PYRAZOLES; SULFONAMIDES; SUPEROXIDE DISMUTASE; SURVIVAL RATE; TREATMENT OUTCOME; UBIQUINONE;

EID: 11144358364     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.01.003     Document Type: Article

References (57)

1. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
2. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., Epstein C.J., Schulz J.B. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 65:1995;919-922.
3. Becher M.W., Kotzuk J.A., Sharp A.H., Davies S.W., Bates G.P., Price D.L., Ross C.A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 4:1998;387-397.
4. Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., Cleveland D.W. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 18:1997;327-338.
5. Burright E.N., Clark H.B., Servadio A., Matilla T., Feddersen R.M., Yunis W.S., Duvick L.A., Zoghbi H.Y., Orr H.T. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 82:1995;937-948.
6. Carlson G.A., Borchelt D.R., Dake A., Turner S., Danielson V., Coffin J.D., Eckman C., Meiners J., Nilsen S.P., Younkin S.G., Hsiao K.K. Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. Hum. Mol. Genet. 6:1997;1951-1959.
7. Chan P.H., Kinouchi H., Epstein C.J., Carlson E., Chen S.F., Imaizumi S., Yang G.Y. Role of superoxide dismutase in ischemic brain injury: reduction of edema and infarction in transgenic mice following focal cerebral ischemia. Prog. Brain Res. 96:1993;97-104.
8. Chan P.H., Epstein C.J., Kinouchi H., Kamii H., Chen S.F., Carlson E., Gafni J., Yang G.Y., Reola L. Neuroprotective role of CuZn-superoxide dismutase in ischemic brain damage. Adv. Neurol. 71:1996;271-280.
9. Chan P.H., Kawase M., Murakami K., Chen S.F., Li Y., Calagui B., Reola L., Carlson E., Epstein C.J. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. J. Neurosci. 18:1998;8292-8299.
10. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
11. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
12. Drachman D.B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52:2002;771-778.
13. Epstein C.J., Avraham K.B., Lovett M., Smith S., Elroy-Stein O., Rotman G., Bry C., Groner Y. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 84:1987;8044-8048.
14. Ferrante R.J., Andreassen O.A., Dedeoglu A., Ferrante K.L., Jenkins B.G., Hersch S.M., Beal M.F. Therapeutic effects of Coenzyme Q10 and Remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22:2002;1592-1599.
15. Groner Y., Lieman-Hurwitz J., Dafni N., Sherman L., Levanon D., Bernstein Y., Danciger E., Elroy-Stein O. Molecular structure and expression of the gene locus on chromosome 21 encoding the Cu/Zn superoxide dismutase and its relevance to Down syndrome. Ann. N.Y. Acad. Sci. 450:1985;133-156.
16. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.-X., Chen W., Zhai P., Sufit R.L., Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
17. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19:1999;2522-2534.
18. Heiser V., Scherzinger E., Boeddrich A., Nordhoff E., Lurz R., Schugardt N., Lehrach H., Wanker E.E. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U. S. A. 97:1999;6739-6744.
19. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51:2002;235-242.
20. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
21. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor Celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275:2000;11397-11403.
22. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
23. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2:1999;157-161.
24. Jankowsky J.L., Savonenko A., Schilling G., Wang J., Xu G., Borchelt D.R. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr. Neurol. Neurosci. Rep. 2:2002;457-464.
25. Kempermann G., Kuhn H.G., Gage F.H. More hippocampal neurons in adult mice living in an enriched environment. Nature. 386:1997;493-495.
26. Kempermann G., Brandon E.P., Gage F.H. Environmental stimulation of 129/SvJ mice causes increased cell proliferation and neurogenesis in the adult dentate gyrus. Curr. Biol. 8:1998;939-942.
27. Kern M.A., Schubert D., Sahi D., Schoneweiss M.M., Moll I., Haugg A.M., Dienes H.P., Breuhahn K., Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology. 36:2002;885-894.
28. Kinouchi H., Epstein C.J., Mizui T., Carlson E., Chen S.F., Chan P.H. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Natl. Acad. Sci. U. S. A. 88:1991;11158-11162.
29. Korth C., May B.C., Cohen F.E., Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9836-9841.
30. Kusunoki N., Yamazaki R., Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by Celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum. 46:2002;3159-3167.
31. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10:2001;137-144.
32. Lunkes A., Mandel J.L. A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 7:1998;1355-1361.
33. Lunkes A., Lindenberg K.S., Ben Haiem L., Weber C., Devys D., Landwehrmeyer G.B., Mandel J.L., Trottier Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell. 10:2002;259-269.
34. Matthews R.T., Yang L., Browne W., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective efforts. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8892-8897.
35. Murakami K., Kondo T., Epstein C.J., Chan P.H. Overexpression of CuZn-superoxide dismutase reduces hippocampal injury after global ischemia in transgenic mice. Stroke. 28:1997;1797-1804.
36. Patti R., Gumired K., Reddanna P., Sutton L.N., Phillips P.C., Reddy C.D. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of Celecoxib and rofecoxib. Cancer Lett. 180:2002;13-21.
37. Perutz M. Polar zippers: their role in human disease. Protein Sci. 3:1994;1629-1637.
38. Poirier M.A., Li H., Macosko J., Cai S., Amzel M., Ross C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277:2002;41032-41037.
39. Ross C.A., Margolis R.L., Rosenblatt A., Ranen N.G., Becher M.W., Aylward E. Huntington disease and the related disorder, dentatorubral- pallidoluysian atrophy (DRPLA). Medicine. 76:1997;305-338.
40. Samlowski W.E., Petersen R., Cuzzocrea S., Macarthur H., Burton D., McGregor J.R., Salvemini D. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat. Med. 9:2003;750-755.
41. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., Hasenbank R., Bates G.P., Davies S.W., Lehrach H., Wanker E.E. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90:1997;549-558.
42. Scherzinger E., Sittler A., Schweiger K., Heiser V., Lurz R., Hasenbank R., Lehrach H., Wanker E.E. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl. Acad. Sci. U. S. A. 96:1999;4604-4609.
43. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic pathology in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:1999;397-407.
44. Schilling G., Coonfield M.L., Ross C.A., Borchelt D.R. Coenzyme Q10 and Remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315:2001;149-153.
45. Schilling G., Jinnah H.A., Gonzales V., Coonfield M.L., Kim Y., Wood J.D., Price D.L., Li X.J., Jenkins N., Copeland N., Moran T., Ross C.A., Borchelt D.R. Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. Neurobiol. Dis. 8:2001;405-418.
46. Sieradzan K.A., Mechan A.O., Jones L., Wanker E.E., Nukina N., Mann D.M. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp. Neurol. 156:1999;92-99.
47. Smith D.L., Portier R., Woodman B., Hockly E., Mahal A., Klunk W.E., Li X.J., Wanker E., Murray K.D., Bates G.P. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis. 8:2001;1017-1026.
48. Sullivan F.R., Bird E.D., Alpay M., Cha J.H. Remotivation therapy and Huntington's disease. J. Neurosci. Nurs. 33:2001;136-142.
49. The Huntington's Study Group A randomized, placebo-controlled trial of Coenzyme Q10 and Remacemide in Huntington's disease. Neurology. 57:2001;397-404.
50. Vajragupta O., Boonchoong P., Sumanont Y., Watanabe H., Wongkrajang Y., Kammasud N. Manganese-based complexes of radical scavengers as neuroprotective agents. Bioorg. Med. Chem. 11:2003;2329-2337.
51. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature. 404:2000;721-722.
52. Vonsattel J.P.G., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
53. Vonsattel J.-P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Jr. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:1985;559-577.
54. Wang J., Xu G., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., Borchelt D.R. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 10:2002;128-138.
55. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
56. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531:2002;278-284.
57. Yu Z.X., Li S.H., Evans J., Pillarisetti A., Li H., Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23:2003;2193-2202.